{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:02:35Z","timestamp":1774620155278,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00467-021-04983-3","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T04:46:38Z","timestamp":1614919598000},"page":"303-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Update on the treatment of steroid-sensitive nephrotic syndrome"],"prefix":"10.1007","volume":"37","author":[{"given":"Federica","family":"Zotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3468","authenticated-orcid":false,"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"4983_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629\u2013639","journal-title":"Lancet"},{"key":"4983_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal Change Disease. Clin J Am Soc Nephrol 12:332\u2013345","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/adc.57.7.544","volume":"57","author":"O Koskimies","year":"1982","unstructured":"Koskimies O, Vilska J, Rapola J, Hallman N (1982) Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57:544\u2013548","journal-title":"Arch Dis Child"},{"key":"4983_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769\u2013776","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2215\/CJN.05950809","volume":"4","author":"P Niaudet","year":"2009","unstructured":"Niaudet P (2009) Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 4:1547\u20131548","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR6","doi-asserted-by":"crossref","unstructured":"(1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159\u2013165","DOI":"10.1038\/ki.1978.23"},{"key":"4983_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00467-017-3677-5","volume":"33","author":"M Colucci","year":"2018","unstructured":"Colucci M, Corpetti G, Emma F, Vivarelli M (2018) Immunology of idiopathic nephrotic syndrome. Pediatr Nephrol 33:573\u2013584","journal-title":"Pediatr Nephrol"},{"key":"4983_CR8","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/adc.27.134.322","volume":"27","author":"GC Arneil","year":"1952","unstructured":"Arneil GC, Wilson HE (1952) Cortisone treatment of nephrosis. Arch Dis Child 27:322\u2013328","journal-title":"Arch Dis Child"},{"key":"4983_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/adc.28.141.372","volume":"28","author":"GC Arneil","year":"1953","unstructured":"Arneil GC, Wilson HE (1953) A.C.T.H. in nephrosis. Arch Dis Child 28:372\u2013380","journal-title":"Arch Dis Child"},{"key":"4983_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00467-003-1176-3","volume":"18","author":"F Emma","year":"2003","unstructured":"Emma F, Sesto A, Rizzoni G (2003) Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol 18:783\u2013788","journal-title":"Pediatr Nephrol"},{"key":"4983_CR12","doi-asserted-by":"crossref","unstructured":"(1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561\u2013564","DOI":"10.1016\/S0022-3476(81)80760-3"},{"key":"4983_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"4983_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/archdischild-2015-308924","volume":"101","author":"N Larkins","year":"2016","unstructured":"Larkins N, Kim S, Craig J, Hodson E (2016) Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child 101:404\u2013408","journal-title":"Arch Dis Child"},{"key":"4983_CR15","first-page":"CD001533","volume":"2007","author":"EM Hodson","year":"2007","unstructured":"Hodson EM, Willis NS, Craig JC (2007) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007:CD001533","journal-title":"Cochrane Database Syst Rev"},{"key":"4983_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274","journal-title":"Kidney Int Suppl"},{"key":"4983_CR17","doi-asserted-by":"publisher","first-page":"l1800","DOI":"10.1136\/bmj.l1800","volume":"365","author":"NJA Webb","year":"2019","unstructured":"Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ, PREDNOS Collaborative Group (2019) Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 365:l1800","journal-title":"BMJ"},{"key":"4983_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/ki.2014.240","volume":"87","author":"A Sinha","year":"2015","unstructured":"Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A (2015) Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87:217\u2013224","journal-title":"Kidney Int"},{"key":"4983_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.2014.260","volume":"87","author":"N Yoshikawa","year":"2015","unstructured":"Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K, Japanese Study Group of Kidney Disease in Children (2015) A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87:225\u2013232","journal-title":"Kidney Int"},{"key":"4983_CR20","first-page":"CD001533","volume":"2020","author":"D Hahn","year":"2020","unstructured":"Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM (2020) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2020:CD001533","journal-title":"Cochrane Database Syst Rev"},{"key":"4983_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","volume":"176","author":"G Desch\u00eanes","year":"2017","unstructured":"Desch\u00eanes G, Vivarelli M, Peruzzi L, ESPN Working Group on Idiopathic Nephrotic Syndrome (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647\u2013654","journal-title":"Eur J Pediatr"},{"key":"4983_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00467-018-3975-6","volume":"33","author":"M Sibley","year":"2018","unstructured":"Sibley M, Roshan A, Alshami A, Catapang M, Jobsis JJ, Kwok T, Polderman N, Sibley J, Matsell DG, Mammen C (2018) Induction prednisone dosing for childhood nephrotic syndrome: how low should we go? Pediatr Nephrol 33:1539\u20131545","journal-title":"Pediatr Nephrol"},{"key":"4983_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00467-014-2903-7","volume":"30","author":"A Pasini","year":"2015","unstructured":"Pasini A, Aceto G, Ammenti A, Ardissino G, Azzolina V, Bettinelli A, Cama E, Cantatore S, Crisafi A, Conti G, D'Agostino M, Dozza A, Edefonti A, Fede C, Groppali E, Gualeni C, Lavacchini A, Lepore M, Maringhini S, Mariotti P, Materassi M, Mencarelli F, Messina G, Negri A, Piepoli M, Ravaglia F, Simoni A, Spagnoletta L, Montini G (2015) Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 30:91\u2013101","journal-title":"Pediatr Nephrol"},{"key":"4983_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00467-008-1089-2","volume":"24","author":"J Feber","year":"2009","unstructured":"Feber J, Al-Matrafi J, Farhadi E, Vaillancourt R, Wolfish N (2009) Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol 24:1027\u20131031","journal-title":"Pediatr Nephrol"},{"key":"4983_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00467-018-4127-8","volume":"34","author":"F Emma","year":"2019","unstructured":"Emma F, Montini G, Gargiulo A (2019) Equations to estimate prednisone dose using body weight. Pediatr Nephrol 34:685\u2013688","journal-title":"Pediatr Nephrol"},{"key":"4983_CR26","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00467-011-1993-8","volume":"26","author":"O Mehls","year":"2011","unstructured":"Mehls O, Hoyer PF (2011) Dosing of glucocorticosteroids in nephrotic syndrome. Pediatr Nephrol 26:2095\u20132098","journal-title":"Pediatr Nephrol"},{"key":"4983_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s004670050344","volume":"11","author":"BK Ekka","year":"1997","unstructured":"Ekka BK, Bagga A, Srivastava RN (1997) Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 11:597\u2013599","journal-title":"Pediatr Nephrol"},{"key":"4983_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1681\/ASN.2012070646","volume":"24","author":"N Teeninga","year":"2013","unstructured":"Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J (2013) Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 24:149\u2013159","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jpeds.2009.12.020","volume":"156","author":"M Vivarelli","year":"2010","unstructured":"Vivarelli M, Moscaritolo E, Tsalkidis A, Massella L, Emma F (2010) Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr 156:965\u2013971","journal-title":"J Pediatr"},{"key":"4983_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.kint.2019.04.006","volume":"96","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Rosado MM, Cascioli S, Bruschi M, Candiano G, Corpetti G, Giardino L, Serafinelli J, Giannone C, Ghiggeri GM, Rastaldi MP, Sitia R, Emma F, Vivarelli M (2019) Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. Kidney Int 96:971\u2013982","journal-title":"Kidney Int"},{"key":"4983_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00467-010-1537-7","volume":"25","author":"RF Andersen","year":"2010","unstructured":"Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S (2010) Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr Nephrol 25:1299\u20131304","journal-title":"Pediatr Nephrol"},{"key":"4983_CR32","first-page":"gfz185","volume":"2019","author":"M Sato","year":"2019","unstructured":"Sato M, Ishikura K, Ando T, Kikunaga K, Terano C, Hamada R, Ishimori S, Hamasaki Y, Araki Y, Gotoh Y, Nakanishi K, Nakazato H, Matsuyama T, Iijima K, Yoshikawa N, Ito S, Honda M (2019) Prognosis and acute complications at the first onset of idiopathic nephrotic syndrome in children: a nationwide survey in Japan (JP-SHINE study). Nephrol Dial Transplant 2019:gfz185","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0272-6386(03)00346-9","volume":"41","author":"M Hiraoka","year":"2003","unstructured":"Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M, West Japan Cooperative Study Group of Kidney Disease in Children (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155\u20131162","journal-title":"Am J Kidney Dis"},{"key":"4983_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.kint.2020.09.024","volume":"99","author":"A Gargiulo","year":"2020","unstructured":"Gargiulo A, Massella L, Ruggiero B, Rava L, Ciofi Degli Atti M, Materassi M, Lugani F, Benetti E, Morello W, Molino D, Mattozzi F, Pennesi M, Maringhini S, Pasini A, Gianoglio B, Pecoraro C, Montini G, Murer L, Ghiggeri GM, Romagnani P, Vivarelli M, Emma F (2020) Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int 99:475\u2013483","journal-title":"Kidney Int"},{"key":"4983_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00467-016-3458-6","volume":"32","author":"K Raja","year":"2017","unstructured":"Raja K, Parikh A, Webb H, Hothi D (2017) Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol 32:99\u2013105","journal-title":"Pediatr Nephrol"},{"key":"4983_CR36","doi-asserted-by":"publisher","first-page":"e018148","DOI":"10.1136\/bmjopen-2017-018148","volume":"7","author":"AM Schijvens","year":"2017","unstructured":"Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar N, van den Heuvel L, Schreuder MF (2017) REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 7:e018148","journal-title":"BMJ Open"},{"key":"4983_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.kint.2018.10.008","volume":"95","author":"M Vivarelli","year":"2019","unstructured":"Vivarelli M, Emma F (2019) Levamisole for children with nephrotic syndrome: new evidence for the use of an \"old\" drug. Kidney Int 95:25\u201328","journal-title":"Kidney Int"},{"key":"4983_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/jcm8060860","volume":"8","author":"AK Muhlig","year":"2019","unstructured":"Muhlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J (2019) Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects. J Clin Med 8:860","journal-title":"J Clin Med"},{"key":"4983_CR39","first-page":"CD002290","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD002290","journal-title":"Cochrane Database Syst Rev"},{"key":"4983_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.kint.2017.08.011","volume":"93","author":"MP Gruppen","year":"2018","unstructured":"Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC (2018) A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 93:510\u2013518","journal-title":"Kidney Int"},{"key":"4983_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.kint.2017.09.024","volume":"93","author":"MJ Kemper","year":"2018","unstructured":"Kemper MJ, Neuhaus TJ (2018) Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand? Kidney Int 93:310\u2013313","journal-title":"Kidney Int"},{"key":"4983_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.kint.2018.08.039","volume":"95","author":"A Sinha","year":"2019","unstructured":"Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A (2019) Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int 95:210\u2013218","journal-title":"Kidney Int"},{"key":"4983_CR43","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00204-017-1947-4","volume":"91","author":"TM Brunt","year":"2017","unstructured":"Brunt TM, van den Berg J, Pennings E, Venhuis B (2017) Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol 91:2303\u20132313","journal-title":"Arch Toxicol"},{"key":"4983_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.semarthrit.2018.07.010","volume":"48","author":"A Dartevel","year":"2019","unstructured":"Dartevel A, Chaigne B, Moachon L, Grenier F, Dupin N, Guillevin L, Bouillet L, Mouthon L (2019) Levamisole-induced vasculopathy: A systematic review. Semin Arthritis Rheum 48:921\u2013926","journal-title":"Semin Arthritis Rheum"},{"key":"4983_CR45","doi-asserted-by":"publisher","first-page":"e024882","DOI":"10.1136\/bmjopen-2018-024882","volume":"8","author":"R Ehren","year":"2018","unstructured":"Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Hocker B, Hoyer PF, Kastner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT (2018) Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ Open 8:e024882","journal-title":"BMJ Open"},{"key":"4983_CR46","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00467-018-3970-y","volume":"33","author":"U Querfeld","year":"2018","unstructured":"Querfeld U, Weber LT (2018) Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol 33:2253\u20132265","journal-title":"Pediatr Nephrol"},{"key":"4983_CR47","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","volume":"22","author":"K Afzal","year":"2007","unstructured":"Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:2059\u20132065","journal-title":"Pediatr Nephrol"},{"key":"4983_CR48","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","volume":"42","author":"A Bagga","year":"2003","unstructured":"Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114\u20131120","journal-title":"Am J Kidney Dis"},{"key":"4983_CR49","first-page":"268","volume":"72","author":"S Fujinaga","year":"2009","unstructured":"Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T (2009) Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72:268\u2013273","journal-title":"Clin Nephrol"},{"key":"4983_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.00550206","volume":"1","author":"RJ Hogg","year":"2006","unstructured":"Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2006) Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1:1173\u20131178","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR51","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00467-005-1957-y","volume":"20","author":"I Novak","year":"2005","unstructured":"Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H (2005) Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:1265\u20131268","journal-title":"Pediatr Nephrol"},{"key":"4983_CR52","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1442-200X.2007.02487.x","volume":"49","author":"M Okada","year":"2007","unstructured":"Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933\u2013937","journal-title":"Pediatr Int"},{"key":"4983_CR53","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020","journal-title":"Pediatr Nephrol"},{"key":"4983_CR54","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, Tonshoff B, Hoyer P, Querfeld U (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"A Hackl","year":"2016","unstructured":"Hackl A, Cseprekal O, Gessner M, Liebau MC, Habbig S, Ehren R, Muller C, Taylan C, Dotsch J, Weber LT (2016) Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference? Ther Drug Monit 38:274\u2013279","journal-title":"Ther Drug Monit"},{"key":"4983_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR57","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00467-010-1717-5","volume":"26","author":"M van Husen","year":"2011","unstructured":"van Husen M, Kemper MJ (2011) New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 26:881\u2013892","journal-title":"Pediatr Nephrol"},{"key":"4983_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2215\/CJN.13071212","volume":"9","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Oba MS, Ito S, Hataya H, Tanaka R, Ohwada Y, Kamei K, Ishikura K, Yata N, Nozu K, Honda M, Nakamura H, Nagata M, Ohashi Y, Nakanishi K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (2014) Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol 9:271\u2013278","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR59","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","volume":"21","author":"MD Sinha","year":"2006","unstructured":"Sinha MD, MacLeod R, Rigby E, Clark AG (2006) Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 21:1848\u20131854","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR60","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","volume":"27","author":"W Wang","year":"2012","unstructured":"Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, Fu H, Du L, Liu A (2012) Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 27:2073\u20132079","journal-title":"Pediatr Nephrol"},{"key":"4983_CR61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00467-003-1170-9","volume":"18","author":"U Vester","year":"2003","unstructured":"Vester U, Kranz B, Zimmermann S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661\u2013664","journal-title":"Pediatr Nephrol"},{"key":"4983_CR62","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/ndt\/gfq405","volume":"26","author":"B Cammas","year":"2011","unstructured":"Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B (2011) Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 26:178\u2013184","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004670000523","volume":"16","author":"K Latta","year":"2001","unstructured":"Latta K, von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271\u2013282","journal-title":"Pediatr Nephrol"},{"key":"4983_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21:193\u2013202","journal-title":"Clin Exp Nephrol"},{"key":"4983_CR65","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308\u20131315","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR66","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033","journal-title":"Kidney Int"},{"key":"4983_CR68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"key":"4983_CR69","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasa M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G (2014) Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25:850\u2013863","journal-title":"J Am Soc Nephrol"},{"key":"4983_CR70","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr 172:757\u2013764","journal-title":"JAMA Pediatr"},{"key":"4983_CR71","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 97:e13157","journal-title":"Medicine"},{"key":"4983_CR72","first-page":"91","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D (2018) NEPHRUTIX: a randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. J Auto Immun 88:91\u2013102","journal-title":"J Auto Immun"},{"key":"4983_CR73","doi-asserted-by":"publisher","unstructured":"Chan EY, Tullus K (2020) Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-020-04609-0","DOI":"10.1007\/s00467-020-04609-0"},{"key":"4983_CR74","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dotsch J (2012) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27:1910\u20131915","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR75","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, Deschenes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083\u20131089","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR76","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28:257\u2013264","journal-title":"Pediatr Nephrol"},{"key":"4983_CR77","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2015) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30:96\u2013106","journal-title":"Nephrol Dial Transplant"},{"key":"4983_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31:589\u2013594","journal-title":"Pediatr Nephrol"},{"key":"4983_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S (2016) Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 31:89\u201395","journal-title":"Pediatr Nephrol"},{"key":"4983_CR80","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207\u20132212","journal-title":"Clin J Am Soc Nephrol"},{"key":"4983_CR81","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321\u20131328","journal-title":"Pediatr Nephrol"},{"key":"4983_CR82","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401","journal-title":"Kidney Int"},{"key":"4983_CR83","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12882-018-1099-7","volume":"19","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K (2018) Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrol 19:302","journal-title":"BMC Nephrol"},{"key":"4983_CR84","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, Saini H, Mitra DK, Bagga A (2018) Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res 84:520\u2013526","journal-title":"Pediatr Res"},{"key":"4983_CR85","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2020","unstructured":"Parmentier C, Delbet JD, Decramer S, Boyer O, Hogan J, Ulinski T (2020) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:455\u2013462","journal-title":"Pediatr Nephrol"},{"key":"4983_CR86","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O, Onetti Muda A, Palma P, Emma F, Vivarelli M (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653","journal-title":"Front Immunol"},{"key":"4983_CR87","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK, Misbah SA, Oni L, Price-Kuehne FE, Salama AD, Workman S, Wrench D, Karim MY (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford) 58:889\u2013896","journal-title":"Rheumatology (Oxford)"},{"key":"4983_CR88","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","volume":"28","author":"AL Sellier-Leclerc","year":"2013","unstructured":"Sellier-Leclerc AL, Belli E, Gu\u00e9rin V, Dorfm\u00fcller P, Desch\u00eanes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28:1875\u20131879","journal-title":"Pediatr Nephrol"},{"key":"4983_CR89","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145\u2013149","journal-title":"Pediatr Nephrol"},{"key":"4983_CR90","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Desch\u00eanes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753\u20131755","journal-title":"Pediatr Nephrol"},{"key":"4983_CR91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytu\u0142a","year":"2010","unstructured":"Prytu\u0142a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25:461\u2013468","journal-title":"Pediatr Nephrol"},{"key":"4983_CR92","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B (2014) Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370:1268\u20131270","journal-title":"N Engl J Med"},{"key":"4983_CR93","doi-asserted-by":"publisher","first-page":"bcr2015210208","DOI":"10.1136\/bcr-2015-210208","volume":"2015","author":"A Bonanni","year":"2015","unstructured":"Bonanni A, Rossi R, Murtas C, Ghiggeri GM (2015) Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep 2015:bcr2015210208","journal-title":"BMJ Case Rep"},{"key":"4983_CR94","doi-asserted-by":"publisher","first-page":"e13413","DOI":"10.1111\/petr.13413","volume":"23","author":"S Solomon","year":"2019","unstructured":"Solomon S, Zolotnitskaya A, Del Rio M (2019) Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child. Pediatr Transplant 23:e13413","journal-title":"Pediatr Transplant"},{"key":"4983_CR95","doi-asserted-by":"publisher","first-page":"e13175","DOI":"10.1111\/petr.13175","volume":"22","author":"J Bernard","year":"2018","unstructured":"Bernard J, Bruel A, Allain-Launay E, Dantal J, Roussey G (2018) Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. Pediatr Transplant 22:e13175","journal-title":"Pediatr Transplant"},{"key":"4983_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00467-016-3498-y","volume":"32","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G (2017) Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol 32:181\u2013184","journal-title":"Pediatr Nephrol"},{"key":"4983_CR97","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"CS Wang","year":"2017","unstructured":"Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B (2017) Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32:835\u2013841","journal-title":"Pediatr Nephrol"},{"key":"4983_CR98","doi-asserted-by":"publisher","first-page":"e013319","DOI":"10.1136\/bmjopen-2016-013319","volume":"7","author":"P Ravani","year":"2017","unstructured":"Ravani P, Bonanni A, Ghiggeri GM (2017) Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open 7:e013319","journal-title":"BMJ Open"},{"key":"4983_CR99","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238\u20131249","journal-title":"Br J Clin Pharmacol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-04983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-04983-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-04983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T21:09:12Z","timestamp":1675026552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-04983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4983"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-04983-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}